Let’s uncover some gems from our specialized screener.<\/p>\n
Overview: Advanced Medical Solutions Group plc develops, manufactures, and distributes products for surgical, woundcare, and wound-closure markets across the UK, Germany, Europe, the US, and internationally with a market cap of \u00a3492.03 million.<\/p>\n
Operations: The company’s revenue is primarily derived from its Surgical segment, which accounts for \u00a3183.45 million, and its Woundcare segment, contributing \u00a345.49 million.<\/p>\n
Estimated Discount To Fair Value: 48.1%<\/p>\n
Advanced Medical Solutions Group is trading at \u00a32.28, significantly below its estimated future cash flow value of \u00a34.39, suggesting undervaluation. The company reported a sales increase to \u00a3228.94 million for 2025, with net income rising to \u00a39.95 million from the previous year. Earnings are forecasted to grow at 41.3% annually, outpacing the UK market’s growth rate of 12.4%. However, return on equity is expected to remain relatively low at 14.4%.<\/p>\n
Overview: GB Group plc, with a market cap of \u00a3513.85 million, offers identity data intelligence products and services across the United Kingdom, the United States, Australia, and other international markets.<\/p>\n Operations: The company generates revenue from three main segments: Identity (\u00a3156.59 million), Location (\u00a386.87 million), and Global Fraud Solutions (\u00a337.90 million).<\/p>\n Estimated Discount To Fair Value: 48.2%<\/p>\n GB Group is trading at \u00a32.21, significantly below its estimated future cash flow value of \u00a34.26, highlighting potential undervaluation. The company recently refinanced a GBP 175 million unsecured Revolving Credit Facility maturing in 2030, enhancing financial flexibility. Despite high-quality earnings impacted by large one-off items, GB Group’s earnings are projected to grow significantly over the next three years at an annual rate of 37%, outpacing the UK market’s growth forecast of 12.2%.<\/p>\n Overview: Oxford Biomedica plc is a contract development and manufacturing organization specializing in delivering therapies globally, with a market cap of approximately \u00a3775 million.<\/p>\n Operations: The company’s revenue is primarily derived from Manufacturing Services (\u00a381.06 million), Development Services (\u00a360.11 million), Procurement Services (\u00a322.30 million), and Licences, Milestones, and Royalties (\u00a35.27 million).<\/p>\n Estimated Discount To Fair Value: 49.8%<\/p>\n Oxford Biomedica is trading at \u00a36.41, well below its estimated future cash flow value of \u00a312.76, suggesting potential undervaluation. The company has launched a fast-track development and manufacturing offering for viral vectors, enhancing its service efficiency and appeal to biotech clients. Despite reporting a net loss of \u00a330.13 million in 2025, Oxford Biomedica’s earnings are projected to grow significantly over the next three years as it becomes profitable, supported by strategic partnerships like the expanded agreement with Bristol Myers Squibb.<\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n Companies discussed in this article include AIM:AMS LSE:GBG and LSE:OXB.<\/p>\n This article was originally published by Simply Wall St<\/a>.<\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"As the UK market grapples with global economic uncertainties, notably influenced by China’s sluggish recovery and its impact…\n","protected":false},"author":2,"featured_media":17541,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[8100,8102,1839,8101,8099,713,8103,5,1843,6],"class_list":{"0":"post-17540","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-uk","8":"tag-advanced-medical-solutions-group","9":"tag-advanced-medical-solutions-group-plc","10":"tag-fair-value","11":"tag-gb-group","12":"tag-oxford-biomedica","13":"tag-solutions","14":"tag-tbc-bank-group","15":"tag-uk","16":"tag-undervalued-stocks","17":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116435724679257918","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/17540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=17540"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/17540\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/17541"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=17540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=17540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=17540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"AIM:AMS](\"https:\/\/www.europesays.com\/britain\/wp-content\/uploads\/2026\/04\/14c63f59be3f44d9ee364770d8eb7786.png\")
<\/a> AIM:AMS Discounted Cash Flow as at Apr 2026 <\/p>\n<\/a> LSE:GBG Discounted Cash Flow as at Apr 2026 <\/p>\n
<\/a> LSE:OXB Discounted Cash Flow as at Apr 2026 <\/p>\n